Ripasudil-brimonidine fixed-dose combination Observational study to Confirm the safety and efficacy of rho Kinase inhibitor and alpha2 adrenergic receptor agonist for long-term use in Japanese patients with glaucoma
Not Applicable
Recruiting
- Conditions
- glaucoma, ocular hypertension
- Registration Number
- JPRN-UMIN000050123
- Lead Sponsor
- Japan society for Patient Reported Outcome
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who had used the ripasudil-brimonidine fixed-dose combination and had discontinued the use of it 2. Patients with a history of hypersensitivity to ripasudil or brimonidine 3. low birth weight infant, newborn infant, infant, or toddler who is younger than 2 years 4. Patients who need regal representatives to give their consent 5. Patients with other conditions that the investigators judge to be inappropriate for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method